JOP20160092B1 - علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية - Google Patents
علاج البيتا ثلاسيميا باستخدام مصطبة لجائنيةInfo
- Publication number
- JOP20160092B1 JOP20160092B1 JOP/2016/0092A JOP20160092A JOP20160092B1 JO P20160092 B1 JOP20160092 B1 JO P20160092B1 JO P20160092 A JOP20160092 A JO P20160092A JO P20160092 B1 JOP20160092 B1 JO P20160092B1
- Authority
- JO
- Jordan
- Prior art keywords
- ligne
- tray
- treatment
- beta thalassemia
- thalassemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562161136P | 2015-05-13 | 2015-05-13 | |
| US201562173836P | 2015-06-10 | 2015-06-10 | |
| US201562243457P | 2015-10-19 | 2015-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20160092B1 true JOP20160092B1 (ar) | 2023-03-28 |
Family
ID=57248528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2016/0092A JOP20160092B1 (ar) | 2015-05-13 | 2016-05-12 | علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180125928A1 (OSRAM) |
| EP (1) | EP3294320A4 (OSRAM) |
| JP (2) | JP6976859B2 (OSRAM) |
| KR (1) | KR102640198B1 (OSRAM) |
| CN (1) | CN107847562A (OSRAM) |
| AU (2) | AU2016261913B2 (OSRAM) |
| CA (1) | CA2985777A1 (OSRAM) |
| HK (1) | HK1251157A1 (OSRAM) |
| IL (2) | IL284686B2 (OSRAM) |
| JO (1) | JOP20160092B1 (OSRAM) |
| MY (1) | MY189601A (OSRAM) |
| PH (1) | PH12017502079A1 (OSRAM) |
| TN (1) | TN2017000468A1 (OSRAM) |
| TW (2) | TWI814187B (OSRAM) |
| WO (1) | WO2016183280A1 (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201692543A1 (ru) | 2005-11-23 | 2017-08-31 | Акселерон Фарма Инк. | Антагонисты активина-actriia и их применение для стимулирования роста кости |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| PT2340031T (pt) | 2008-08-14 | 2019-07-25 | Acceleron Pharma Inc | Armadilhas de gdf para uso no tratamento de anemia |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| WO2011063018A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| BR112016029226A2 (pt) | 2014-06-13 | 2017-10-17 | Acceleron Pharma Inc | métodos e composições para o tratamento de úlceras |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| FI3227675T3 (fi) | 2014-12-03 | 2023-05-25 | Celgene Corp | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| JP7072507B2 (ja) | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | 眼の障害を処置するための方法 |
| RU2748278C2 (ru) | 2016-07-15 | 2021-05-21 | Акселерон Фарма Инк. | Композиции и способы лечения легочной гипертензии |
| MX2019001043A (es) | 2016-07-27 | 2019-09-26 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de la mielofibrosis. |
| JP7051846B2 (ja) | 2016-11-10 | 2022-04-11 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 |
| HUE068733T2 (hu) * | 2017-06-14 | 2025-01-28 | Celgene Corp | Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére |
| JP7258021B2 (ja) | 2017-11-09 | 2023-04-14 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体を含む医薬組成物 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| EP3788065B1 (en) | 2018-04-30 | 2025-08-27 | The Children's Hospital Of Philadelphia | Improving anemias by combining agents |
| CA3098679A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN112969471A (zh) * | 2018-10-31 | 2021-06-15 | 细胞基因公司 | 使用激活素-actrii配体陷阱治疗具有环状铁粒幼细胞的受试者中由极低、低或中等风险的骨髓增生异常综合征引起的贫血 |
| CN114302882A (zh) | 2019-07-19 | 2022-04-08 | 威佛（国际）股份公司 | 用于治疗输血依赖型β-地中海贫血（tdt）的膜铁转运蛋白抑制剂 |
| CN112924684B (zh) * | 2019-12-05 | 2022-07-29 | 中国科学院大连化学物理研究所 | 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒 |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| BR112022020628A2 (pt) * | 2020-04-13 | 2022-11-29 | Celgene Corp | Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| EP4240399A4 (en) * | 2020-11-06 | 2024-10-09 | Acceleron Pharma Inc. | FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS |
| EP4274600A4 (en) * | 2021-01-08 | 2024-11-20 | Acceleron Pharma Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY HYPERTENSION |
| JP2024504349A (ja) | 2021-01-20 | 2024-01-31 | ビフォー （インターナショナル） エージー | 骨髄異形成症候群（ｍｄｓ）の処置において使用するためのフェロポーチン阻害剤 |
| WO2025003139A1 (en) | 2023-06-26 | 2025-01-02 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh) |
| WO2025122830A1 (en) * | 2023-12-08 | 2025-06-12 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii signaling inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4247A (en) * | 1845-11-01 | Jordan l | ||
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| EP2124999B1 (en) * | 2006-12-18 | 2012-10-03 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for treating anemia |
| KR20220002710A (ko) * | 2008-06-26 | 2022-01-06 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
| PT2340031T (pt) * | 2008-08-14 | 2019-07-25 | Acceleron Pharma Inc | Armadilhas de gdf para uso no tratamento de anemia |
| BR112012005225B8 (pt) * | 2009-09-09 | 2023-01-10 | Acceleron Pharma Inc | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente |
| DK3875104T3 (da) * | 2011-10-17 | 2025-02-03 | Acceleron Pharma Inc | Sammensætninger til behandling af ineffektiv erytropoiese |
| CA2868466A1 (en) * | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate-2-sulfatase |
| CN112957462A (zh) * | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血的方法 |
| JP6401171B2 (ja) * | 2012-10-24 | 2018-10-03 | セルジーン コーポレイション | 貧血の治療に使用するためのバイオマーカー |
| PT3502240T (pt) * | 2012-11-27 | 2021-08-11 | Childrens Medical Ct Corp | Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal |
-
2016
- 2016-05-12 EP EP16793499.1A patent/EP3294320A4/en active Pending
- 2016-05-12 AU AU2016261913A patent/AU2016261913B2/en active Active
- 2016-05-12 HK HK18110608.3A patent/HK1251157A1/zh unknown
- 2016-05-12 US US15/573,177 patent/US20180125928A1/en not_active Abandoned
- 2016-05-12 MY MYPI2017704290A patent/MY189601A/en unknown
- 2016-05-12 WO PCT/US2016/031999 patent/WO2016183280A1/en not_active Ceased
- 2016-05-12 TW TW110148304A patent/TWI814187B/zh active
- 2016-05-12 CN CN201680041002.2A patent/CN107847562A/zh active Pending
- 2016-05-12 TW TW105114763A patent/TWI762444B/zh active
- 2016-05-12 JO JOP/2016/0092A patent/JOP20160092B1/ar active
- 2016-05-12 JP JP2017559025A patent/JP6976859B2/ja not_active Expired - Fee Related
- 2016-05-12 KR KR1020177035838A patent/KR102640198B1/ko active Active
- 2016-05-12 TN TNP/2017/000468A patent/TN2017000468A1/en unknown
- 2016-05-12 CA CA2985777A patent/CA2985777A1/en active Pending
- 2016-05-12 IL IL284686A patent/IL284686B2/en unknown
-
2017
- 2017-11-08 IL IL255527A patent/IL255527B/en unknown
- 2017-11-16 PH PH12017502079A patent/PH12017502079A1/en unknown
-
2021
- 2021-08-13 JP JP2021131870A patent/JP2021191755A/ja active Pending
- 2021-10-29 AU AU2021258087A patent/AU2021258087B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ737043A (en) | 2025-02-28 |
| TW201709927A (zh) | 2017-03-16 |
| AU2016261913A1 (en) | 2017-11-30 |
| PH12017502079A1 (en) | 2018-06-11 |
| AU2021258087A1 (en) | 2021-11-25 |
| TN2017000468A1 (en) | 2019-04-12 |
| WO2016183280A1 (en) | 2016-11-17 |
| AU2016261913B2 (en) | 2021-08-12 |
| IL255527A (en) | 2018-01-31 |
| EP3294320A4 (en) | 2018-12-26 |
| TWI814187B (zh) | 2023-09-01 |
| TW202231294A (zh) | 2022-08-16 |
| IL284686B2 (en) | 2023-05-01 |
| IL255527B (en) | 2021-07-29 |
| MY189601A (en) | 2022-02-18 |
| AU2021258087B2 (en) | 2023-04-27 |
| KR102640198B1 (ko) | 2024-02-23 |
| US20180125928A1 (en) | 2018-05-10 |
| EP3294320A1 (en) | 2018-03-21 |
| CN107847562A (zh) | 2018-03-27 |
| IL284686B (en) | 2023-01-01 |
| HK1251157A1 (zh) | 2019-01-25 |
| JP2018520094A (ja) | 2018-07-26 |
| IL284686A (en) | 2021-08-31 |
| JP6976859B2 (ja) | 2021-12-08 |
| JP2021191755A (ja) | 2021-12-16 |
| TWI762444B (zh) | 2022-05-01 |
| KR20180006437A (ko) | 2018-01-17 |
| CA2985777A1 (en) | 2016-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20160092B1 (ar) | علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| PH12017500583B1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| MX2018006223A (es) | Moduladores de ror-gamma. | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| ZA202102438B (en) | Melflufen dosage regimens for cancer | |
| PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| MX376029B (es) | Compuestos de isoindol. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| ECSP16095557A (es) | Métodos para tratar infecciones | |
| RU2014107146A (ru) | Способ профилактики канцерогенного действия диэтилнитрозамина у экспериментальных животных | |
| CR20160591A (es) | Metodos para tratar infecciones | |
| AR104621A1 (es) | TRATAMIENTO DE LA b-TALASEMIA POR EL USO DE TRAMPAS DE LIGANDO ActRII | |
| IN2014DE00822A (OSRAM) | ||
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
| PH12014000105A1 (en) | Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен |